Martin, a cancer survivor who led PacBio (NASDAQ: PACB) through its $200 million initial public offering in October 2010, will remain on PacBio’s (NASDAQ: PACB) board through the company’s next annual shareholders meeting, the company said.
PacBio started shipping its next-generation DNA sequencing system in April, but in September laid off 130 employees after disappointing initial sales.
No comments:
Post a Comment